Preferred Label : Anti-survivin T-cell Receptor/Anti-CD3 Bispecific Therapeutic ABBV-184;
NCIt synonyms : Survivin TCR/CD3 Bispecific Therapeutic ABBV-184; Anti-survivin TCR/Anti-CD3 Bispecific Therapeutic ABBV-184;
NCIt definition : A T-cell redirecting bispecific therapeutic composed of a T-cell receptor (TCR) moiety
specific for the tumor-associated antigen (TAA) survivin and a CD3 binding moiety,
with potential immunostimulating and antineoplastic activities. Upon administration
of anti-survivin TCR/anti-CD3 bispecific therapeutic ABBV-184, the TCR moiety of this
agent targets and binds to survivin on tumor cells and the anti-CD3 moiety binds to
CD3-expressing T-lymphocytes. This selectively cross-links tumor cells and T-lymphocytes
and results in a CTL-mediated killing of survivin-expressing tumor cells. Survivin,
a member of the inhibitor of apoptosis (IAP) family expressed during embryonic development,
is upregulated in a variety of human cancers while absent in most normal adult cells;
its expression in tumors is associated with a more aggressive phenotype, decreased
survival, and increased resistance to chemotherapy.;
Molecule name : ABBV-184; ABBV 184;
NCI Metathesaurus CUI : CL1412927;
Origin ID : C175601;
UMLS CUI : C5446652;
Semantic type(s)
- concept_is_in_subset
